Cellomics Expands European Operations Through User Group Implementation and Expanded Support Groups.

PITTSBURGH -- As the leader and founder of HCS, Cellomics, Inc. is pleased to announce the expansion of their European training, service and support operations. As part of this expanded European focus, Cellomics has added new people and new programs to its repertoire of support services for Europe.

An example of new programs being executed in Europe was seen last week in London where Cellomics personnel held the first-ever European User Group meeting. This meeting featured attendance by more than 60 scientists who are utilizing HCS technologies across Europe, and included talks from five different scientists that highlighted various biological applications utilizing HCS to further their drug discovery and cell-based assay efforts. In addition, Cellomics employees from both Europe and North America participated to discuss such items as biology-focused forums, effective implementation of HCS across various therapeutic groups, usability improvements, and future trends.

"Because we are a company solely focused on high content cellular analysis, this User Group meeting is critical to us and our customers. This is the ideal forum for us to interact with our customers and give them an opportunity to share their experiences of implementing HCS to further their drug discovery efforts," says Dan Calvo, President and CEO of Cellomics. "Our employees and customers represent the largest pool of high content screening and analysis knowledge available. The user group allows our customers to share valuable knowledge which will help perpetuate their successful use of HCS technology, while simultaneously helping us to better meet the needs of our customers by providing insight on future requirements."

In addition to the User Group, Cellomics' is pleased to announce an expansion of the European Sales, Service and Support organization. "New employees have been hired to help support our customers from the feasibility/evaluation stage all the way through to the assay development, training and productivity stages of HCS implementation." Commented David Sharp, Director, European Sales and Service, "In the last year, we have doubled the size of our European-based team. This gives us the ability to meet the needs of our expanding customer base and provide more Europe-specific support. We expect that last week's user group will be the first of many such successful events for our European customers."

About Cellomics

Cellomics, Inc. is automating drug discovery through a unique, cell-based assay platform that addresses the needs of Drug Discovery and Systems Biology groups by offering complete systems for High Content Screening (HCS). The platform includes HCS instrumentation (both fixed end-point and kinetic systems), informatics, cellular image analysis software (BioApplications), fluorescent reagents, kits, cell lines, and multiparametric assays. When applied to early drug discovery, this platform is proving to reduce the 'idea-to-discovery' cycle time in drug discovery, while increasing the probability of the therapeutic success of leads as well as enhancing throughput in systems biology and basic research. Cellomics' proprietary platforms, including the ArrayScan(R) and KineticScan(R) HCS Readers, along with BioApplications software and High Content Informatics (HCi(TM)) suite, are in use at multiple sites within all of the top fifteen pharmaceutical companies, as well as leading pharmaceutical and biotechnology companies and academic centers globally. For more information about Cellomics, visit our website at www.cellomics.com.